About Our Fund

YAFO Capital Healthcare Fund actively invests in innovative companies within all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health, partnering with those that have strong growth potential in China/Japan market. Our mission is to bridge the gap between undercapitalized life science projects, companies, and investors through direct investment and/or licensing/co-development arrangements.
Our exit strategy is that we leverage our network with established pharmaceutical companies in China and Japan to seek potential exit or partnering.
Our expert team of international biopharma executives, advisors and investors offer cross-cultural expertise while navigating entry into Asian markets and access to additional resources and funds.
Funding technology enterprises with high growth potential and supporting their leaders enables us to boost innovation in China/Japan life science industry, a huge market to explore.
• Investing directly through our own growth capital fund
• Structured buy-out fund for mature stage companies
Fund Management Certificate

Our extensive network and connections help investees at various stages of their growth

Extensive Network and Connections in China

China Market Provides a Large Market for Innovative Drugs


China Summit-YAFO Healthcare Fund aims to help foreign capital to invest in Chinese innovative biopharma companies who have an offshore structure (e.g. Cayman, HK, etc) and plan to IPO on HK or Nasdaq in the future. We believe this is the perfect timing for a U.S. dollar fund to capture the opportunities of China's healthcare and biotech companies.

Portfolio companies of China Summit Fund

Contact Us

Contact us (qli@yafocapital.com) to learn more about the potential of your product in China Market.